2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T835,The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score accurately predicts prostate cancer (PC) specific mortality (PCSM) in patients with newly diagnosed clinically localized PC. We evaluated the performance of P-score to predict PCSM in a large, multiethnic cohort from the Veterans' Administration (VA). After pathologic review to ensure sufficient tumor tissue, formalin-fixed paraffin-embedded (FFPE) biopsy cores from patients with newly diagnosed PC at the Durham VA were sent to an academic medical center. There, cores were sectioned, RNA extracted, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) tests conducted for IGFBP3, F3, VGLL3, and GAPDH (control). Results were combined with clinical data to generate P-scores. The association between P-score and PCSM was evaluated using c-index, Cox and Fine-Gray models, and decision curve analysis (DCA). Higher P-scores were significantly associated with a higher risk of PCSM (HR = 1.48 per 1 unit increase in P-score, 95% CI: 1.20-1.84, p <0.001) and accurately estimated PCSM (c-index = 0.87). Adding clinical variables to P-score only incrementally improved accuracy. The DCA indicated P-score provided net clinical benefit for patients with PCSM risk between 5% and ~50%. As P-score strongly correlated with risk group, we tested the value of P-score in intermediate-risk patients specifically, where it significantly predicted PCSM (HR 1.43, 95% CI: 1.09-1.86, p = 0.009). In this American cohort of veterans, P-score significantly predicted PCSM. Adding clinical variables minimally improved accuracy. Accuracy remained high in intermediate-risk patients, wherein there is arguably the greatest need for better risk stratification. Given P-scores can be generated rapidly in-house using a standardized RT-qPCR assay, P-score represents a robust new tool to risk-stratify newly diagnosed patients for PC death, thereby minimizing mismatched treatments.31:Tb42, Background The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score accurately predicts prostate cancer (PC) specific mortality (PCSM) in patients with newly diagnosed clinically localized PC. We evaluated the performance of P-score to predict PCSM in a large, multiethnic cohort from the Veterans’ Administration (VA). Methods After pathologic review to ensure sufficient tumor tissue, formalin-fixed paraffin-embedded (FFPE) biopsy cores from patients with newly diagnosed PC at the Durham VA were sent to an academic medical center. There, cores were sectioned, RNA extracted, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) tests conducted for IGFBP3, F3, VGLL3, and GAPDH (control). Results were combined with clinical data to generate P-scores. The association between P-score and PCSM was evaluated using c-index, Cox and Fine-Gray models, and decision curve analysis (DCA). Results Higher P-scores were significantly associated with a higher risk of PCSM (HR = 1.48 per 1 unit increase in P-score, 95% CI: 1.20–1.84, p <0.001) and accurately estimated PCSM (c-index = 0.87). Adding clinical variables to P-score only incrementally improved accuracy. The DCA indicated P-score provided net clinical benefit for patients with PCSM risk between 5% and ~50%. As P-score strongly correlated with risk group, we tested the value of P-score in intermediate-risk patients specifically, where it significantly predicted PCSM (HR 1.43, 95% CI: 1.09–1.86, p = 0.009). Conclusion In this American cohort of veterans, P-score significantly predicted PCSM. Adding clinical variables minimally improved accuracy. Accuracy remained high in intermediate-risk patients, wherein there is arguably the greatest need for better risk stratification. Given P-scores can be generated rapidly in-house using a standardized RT-qPCR assay, P-score represents a robust new tool to risk-stratify newly diagnosed patients for PC death, thereby minimizing mismatched treatments. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Genomic Classifier: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Genomic Classifier (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Genomic%20Classifier\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Genomic Classifier\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Genomic%20Classifier\"}]}}"}}]],["$","$L2f",null,{"title":"Genomic Classifier: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Genomic Classifier — concise summaries and practical next steps.","papers":[{"doi":"10.1016/j.urolonc.2026.07.008","pmid":"42567796","title":"Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination","journal_title":"Urologic Oncology: Seminars and Original Investigations","journal_issn":"1078-1439","published_at":"2026-08-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.urolonc.2026.07.008","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-23T07:33:06.211Z","updated_at":"2026-08-23T07:33:06.211Z","tags":[{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"brand","value":"Oncotype DX Genomic Prostate Score","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"generic","value":"Genomic Prostate Score","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"modality","value":"Genomic Classifier","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"modality","value":"Radical Prostatectomy","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"sample_size","value":"n=418","value_numeric":418},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"warning","value":"GPS was applied retrospectively to archived specimens; pre-analytical variability may affect score accuracy.","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"warning","value":"Study design is labeled retrospective cohort, but the event-enriched sampling strategy introduces elements of a case-cohort design — the study_design tag reflects the authors' framing.","value_numeric":null},{"paper_doi":"10.1016/j.urolonc.2026.07.008","tag_type":"warning","value":"The cohort is event-enriched (24% metastasis rate), which is much higher than typical RP populations — absolute risk estimates and HRs may not translate directly to unselected clinical cohorts.","value_numeric":null}],"summaries":{"what_studied":"In 418 men from an event-enriched radical prostatectomy (RP) cohort (1987–2004), this study evaluated whether adding Genomic Prostate Score (GPS), cribriform size, and Grade Group to quantitative unfavorable histology burden (UH%) improves 15-year metastasis prediction.","key_result":"UH% alone yielded a c-index of ~0.85 for 15-year metastasis prediction; adding GPS and cribriform size raised this to 0.901. UH ≥10% carried an HR of 50.95 (95% CI 10.4–249), and all 102 metastatic events (24%) occurred exclusively in UH-positive tumors.","limitations":"Retrospective, single-institution cohort with centralized pathology review limits generalizability; event-enriched design inflates event rate relative to typical clinical populations; long accrual window (1987–2004) may not reflect contemporary surgical or pathological practice.","practice_takeaway":"Quantitative unfavorable histology burden (UH%) should anchor post-RP risk stratification — it outperforms Grade Group, stage, and genomic classifiers alone. GPS and cribriform size offer marginal refinement but are unlikely to change management once UH burden is known."}},{"doi":"10.1016/j.euo.2026.06.008","pmid":"42350192","title":"Genomic Prostate Score for Identifying Biologically Low-risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy","journal_title":"European Urology Oncology","journal_issn":"2588-9311","published_at":"2026-06-25T00:00:00.000Z","url":"https://doi.org/10.1016/j.euo.2026.06.008","source_score":19,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-02T13:33:10.752Z","updated_at":"2026-07-02T13:33:10.752Z","tags":[{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"generic","value":"Genomic Prostate Score","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"modality","value":"Genomic Classifier","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"sample_size","value":"n=409","value_numeric":409},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"warning","value":"Median follow-up is reported as '≥6 yr' without a precise value, limiting precision of survival estimates.","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"warning","value":"No brand name is associated with the 17-gene Genomic Prostate Score in the abstract; the Oncotype DX Genomic Prostate Score (GPS) is the commonly known commercial assay, but this was not explicitly stated in the source text.","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"warning","value":"The 'discordant low-risk' and 'concordant low-risk' phenotype definitions are study-specific constructs and not established clinical categories.","value_numeric":null},{"paper_doi":"10.1016/j.euo.2026.06.008","tag_type":"warning","value":"The paper's DOI includes '2026' which matches the publication date; this is a very recently published study and has not yet undergone external validation or replication.","value_numeric":null}],"summaries":{"what_studied":"This retrospective study evaluated the 17-gene Genomic Prostate Score (GPS) in 409 patients with clinically localised or locally advanced prostate cancer managed with active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT), with a median follow-up ≥6 years, to assess its potential for guiding management de-escalation.","key_result":"Low GPS scores (present in 58% of the cohort) identified a 'discordant low-risk' phenotype—patients with NCCN ≥2 but low GPS—in 46% of NCCN≥2 AS, 57% of NCCN≥3 RP, 36% of NCCN≥4 RT, and 48% of NCCN5 locally advanced patients; 6-year event-free survival in these discordant low-risk groups was 88% (AS), 100% (RP and RT), and 95% (locally advanced), comparable to 100% 6-year treatment-free survival in concordant low-risk patients.","limitations":"Retrospective design limits causal inference; no randomized de-escalation arm was tested; the study does not establish GPS-guided de-escalation as standard of care, only supports feasibility of future trials.","practice_takeaway":"In patients with higher NCCN risk categories, a low GPS score may identify a substantial subset with favorable 6-year outcomes—consider GPS testing when results could influence the decision to de-escalate treatment intensity. Prospective trials are still needed before routine de-escalation based on GPS alone."}},{"doi":"10.1002/pros.70202","pmid":"42190028","title":"Characterizing the Activity of Inflammasome‐Related Genes and Their Association With Oncological Outcomes in Prostate Cancer","journal_title":"The Prostate","journal_issn":"0270-4137","published_at":"2026-05-26T00:00:00.000Z","url":"https://doi.org/10.1002/pros.70202","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-04T13:23:38.140Z","updated_at":"2026-06-04T13:23:38.140Z","tags":[{"paper_doi":"10.1002/pros.70202","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"brand","value":"Decipher","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"modality","value":"Genomic Classifier","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"sample_size","value":"n=52266","value_numeric":52266},{"paper_doi":"10.1002/pros.70202","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"warning","value":"HSP90AB1 is primarily known as a heat-shock protein chaperone, not a canonical inflammasome component — its classification as 'inflammasome-related' may reflect a broader inflammatory pathway definition used by the authors.","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"warning","value":"NLRP3's U-shaped association with metastasis-free survival is unusual and may reflect non-linear biology or statistical artifact; interpret with caution.","value_numeric":null},{"paper_doi":"10.1002/pros.70202","tag_type":"warning","value":"The GRID cohort (n=52,266) was used for expression analysis only; survival outcomes were analyzed in the smaller META855 cohort — these are distinct populations with different statistical power.","value_numeric":null}],"summaries":{"what_studied":"This study characterized the expression of 34 inflammasome-related genes in a large radical prostatectomy (RP) cohort (Decipher GRID, n=52,266) and evaluated their association with metastasis-free survival in a retrospective outcomes cohort (META855, n=855 RP patients).","key_result":"On multivariable Cox regression, higher AIM2 expression (HR 1.75) and higher HSP90AB1 expression (HR 1.60) were significantly associated with shorter time to metastasis after RP. Notably, both high and low NLRP3 expression were associated with *better* metastasis-free survival compared to average expression.","limitations":"Retrospective design with de-identified registry data limits causal inference. The outcomes cohort (META855, n=855) is relatively modest given the heterogeneity of PCa, and functional validation of inflammasome pathways is lacking.","practice_takeaway":"AIM2 and HSP90AB1 expression may serve as prognostic biomarkers for metastasis risk after RP and warrant prospective validation. NLRP3's non-linear association with outcomes suggests caution before using it as a simple prognostic marker."}},{"doi":"10.1038/s41391-025-01070-8","pmid":"41501560","title":"Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort","journal_title":"Prostate Cancer and Prostatic Diseases","journal_issn":"1365-7852","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1038/s41391-025-01070-8","source_score":27,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-09","doi":"10.1038/s41391-025-01070-8","days":"14","issn":"1365-7852","rank":"4","field":"Clinical Medicine","score":"27","category":"Urology & Nephrology","categories":["Urology & Nephrology"],"_categories":["Urology & Nephrology"]},"pubmed":{"doi":"10.1038/s41391-025-01070-8","title":"Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort.","journal":"Prostate cancer and prostatic diseases","methods":"","results":"Higher P-scores were significantly associated with a higher risk of PCSM (HR = 1.48 per 1 unit increase in P-score, 95% CI: 1.20-1.84, p <0.001) and accurately estimated PCSM (c-index = 0.87). Adding clinical variables to P-score only incrementally improved accuracy. The DCA indicated P-score provided net clinical benefit for patients with PCSM risk between 5% and ~50%. As P-score strongly correlated with risk group, we tested the value of P-score in intermediate-risk patients specifically, where it significantly predicted PCSM (HR 1.43, 95% CI: 1.09-1.86, p = 0.009).","abstract":"$30","keywords":[],"pubmed_id":"41501560","conclusions":"In this American cohort of veterans, P-score significantly predicted PCSM. Adding clinical variables minimally improved accuracy. Accuracy remained high in intermediate-risk patients, wherein there is arguably the greatest need for better risk stratification. Given P-scores can be generated rapidly in-house using a standardized RT-qPCR assay, P-score represents a robust new tool to risk-stratify newly diagnosed patients for PC death, thereby minimizing mismatched treatments.","publication_date":"2026-01-08T00:00:00"},"crossref":{"DOI":"10.1038/s41391-025-01070-8","URL":"https://doi.org/10.1038/s41391-025-01070-8","ISSN":["1365-7852","1476-5608"],"link":[{"URL":"https://www.nature.com/articles/s41391-025-01070-8.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41391-025-01070-8","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41391-025-01070-8.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort"],"author":[{"given":"Alexandra","family":"Mack","sequence":"first","affiliation":[]},{"given":"Trung Duong","family":"Tran","sequence":"additional","affiliation":[]},{"given":"Emelie","family":"Berglund","sequence":"additional","affiliation":[]},{"given":"Gerald L.","family":"Andriole","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Alley","sequence":"additional","affiliation":[]},{"given":"Anthony E.","family":"Sisk","sequence":"additional","affiliation":[]},{"given":"Iveth","family":"Estrada-Reyes","sequence":"additional","affiliation":[]},{"given":"Kara","family":"Bissell","sequence":"additional","affiliation":[]},{"given":"Haleigh","family":"Bellerose","sequence":"additional","affiliation":[]},{"given":"Aubrey","family":"Jarman","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Hoffmeyer","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Burns","sequence":"additional","affiliation":[]},{"given":"Sergio","family":"Sanders","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Vail","sequence":"additional","affiliation":[]},{"given":"Andy","family":"Pao","sequence":"additional","affiliation":[]},{"given":"Raja","family":"Khurram","sequence":"additional","affiliation":[]},{"given":"Amal","family":"Ahmed","sequence":"additional","affiliation":[]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1,7]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:19:29Z","timestamp":1767802769000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T17:24:24Z","timestamp":1767806664631,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s41391-025-01070-8"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"30 July 2025"},{"name":"revised","group":{"name":"ArticleHistory","label":"Article History"},"label":"Revised","order":2,"value":"28 November 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":3,"value":"10 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":4,"value":"7 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"Two authors, Emelie Berglund, PhD and Gerald L. Andriole, MD, are from Prostatype Genomics, the entity developing the Prostatype Test evaluated in this study."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"},"order":2,"value":"The study was approved by the ethics committee of Cedars-Sinai (IRB #STUDY00002370) on 7/6/23. Written informed consent was obtained from all individual participants included in the study. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendmen comparable ethical standards."}],"deposited":{"date-time":"2026-01-07T16:19:30Z","timestamp":1767802770000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"1365-7852"},{"type":"electronic","value":"1476-5608"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1038/pcan.2013.57","key":"1070_CR1","year":"2014","issue":null,"author":"Z Peng","volume":"17","first-page":"81","unstructured":"Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer Prostatic Dis. 2014;17:81–90.","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0145545","key":"1070_CR2","year":"2016","issue":null,"author":"Z Peng","volume":"11","first-page":"e0145545","unstructured":"Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, et al. Improving the prediction of prostate cancer overall survival by supplementing readily available clinical data with gene expression levels of IGFBP3 and F3 in formalin-fixed paraffin embedded core needle biopsy material. PLoS ONE. 2016;11:e0145545.","article-title":null,"journal-title":"PLoS ONE","doi-asserted-by":"publisher"},{"DOI":null,"key":"1070_CR3","year":"2022","issue":null,"author":"F Soderdahl","volume":"14","first-page":"203","unstructured":"Soderdahl F, Xu LD, Bring J, Haggman M. A novel risk score (P-score) based on a three-gene signature, for estimating the risk of prostate cancer-specific mortality. Res Rep Urol. 2022;14:203–217.","article-title":null,"journal-title":"Res Rep Urol","doi-asserted-by":null},{"DOI":"10.1002/bco2.70026","key":"1070_CR4","year":"2025","issue":null,"author":"ST Pang","volume":"6","first-page":"e70026","unstructured":"Pang ST, Lin PH, Berglund E, Xu L, Shao IH, Yu KJ, et al. First validation of the Prostatype® P-score in an Asian cohort: improving risk stratification for prostate cancer. BJUI Compass. 2025;6:e70026.","article-title":null,"journal-title":"BJUI Compass","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.acuroe.2025.501788","key":"1070_CR5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"González-Peramato P, Álvarez-Maestro M, Heredia-Soto V, Mendiola Sabio M, Linares E, Serrano Á, et al. Comparing Prostatype P-score and traditional risk models for predicting prostate cancer outcomes in Spain. Actas Urol Esp (Engl Ed). 2025;49:501788.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1002/pros.24530","key":"1070_CR6","year":"2023","issue":null,"author":"A Saemundsson","volume":"83","first-page":"1133","unstructured":"Saemundsson A, Xu LD, Meisgen F, Cao R, Ahlgren G. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients. Prostate. 2023;83:1133–40.","article-title":null,"journal-title":"Prostate","doi-asserted-by":"publisher"},{"DOI":null,"key":"1070_CR7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NCCN. NCCN clinical practice guidelines in oncology: prostate cancer. 2025 [cited 2025 October 1]; Version 2.2026. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1371/journal.pone.0109610","key":"1070_CR8","year":"2014","issue":null,"author":"Z Peng","volume":"9","first-page":"e109610","unstructured":"Peng Z, Andersson K, Lindholm J, Bodin I, Pramana S, Pawitan Y, et al. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS ONE. 2014;9:e109610.","article-title":null,"journal-title":"PLoS ONE","doi-asserted-by":"publisher"},{"DOI":"10.1002/pros.24523","key":"1070_CR9","year":"2023","issue":null,"author":"P Röbeck","volume":"83","first-page":"831","unstructured":"Röbeck P, Xu L, Ahmed D, Dragomir A, Dahlman P, Häggman M, et al. P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer. Prostate. 2023;83:831–9.","article-title":null,"journal-title":"Prostate","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.115.017719","key":"1070_CR10","year":"2016","issue":null,"author":"PC Austin","volume":"133","first-page":"601","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–9.","article-title":null,"journal-title":"Circulation","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.1997.03540420041027","key":"1070_CR11","year":"1997","issue":null,"author":"AW Partin","volume":"277","first-page":"1445","unstructured":"Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–51.","article-title":null,"journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2017.10.036","key":"1070_CR12","year":"2018","issue":null,"author":"V Cucchiara","volume":"73","first-page":"572","unstructured":"Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73:572–82.","article-title":null,"journal-title":"Eur Urol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-019-0197-3","key":"1070_CR13","year":"2020","issue":null,"author":"LE Howard","volume":"23","first-page":"419","unstructured":"Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, Spratt DE, et al. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer Prostatic Dis. 2020;23:419–28.","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(10)70295-3","key":"1070_CR14","year":"2011","issue":null,"author":"J Cuzick","volume":"12","first-page":"245","unstructured":"Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.","article-title":null,"journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2022.06.101","key":"1070_CR15","year":"2023","issue":null,"author":"JL Janes","volume":"115","first-page":"120","unstructured":"Janes JL, Boyer MJ, Bennett JP, Thomas VM, De Hoedt AM, Edwards VD, et al. The 17-gene genomic prostate score test is prognostic for outcomes after primary external beam radiation therapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115:120–31.","article-title":null,"journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40273-024-01466-9","key":"1070_CR16","year":"2025","issue":null,"author":"A Fridhammar","volume":"43","first-page":"509","unstructured":"Fridhammar A, Frisell O, Wahlberg K, Berglund E, Röbeck P, Persson S. Prognostic testing for prostate cancer—a cost-effectiveness analysis comparing a prostatype P-Score Biomarker approach to standard clinical practice. Pharmacoeconomics. 2025;43:509–20.","article-title":null,"journal-title":"Pharmacoeconomics","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1070"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Prostate Cancer and Prostatic Diseases"],"reference-count":16,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":16,"short-container-title":["Prostate Cancer Prostatic Dis"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1038/s41391-025-01070-8","is_oa":true,"title":"Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://www.nature.com/articles/s41391-025-01070-8.pdf","pmh_id":null,"url_for_pdf":"https://www.nature.com/articles/s41391-025-01070-8.pdf","url_for_landing_page":"https://doi.org/10.1038/s41391-025-01070-8"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"brand","value":"Prostatype","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"modality","value":"Genomic Classifier","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"sample_size","value":"n=160","value_numeric":160},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"warning","value":"Design inferred as a retrospective cohort validation from a single VA center; multivariable modeling was limited by only 14 prostate cancer deaths.","value_numeric":null},{"paper_doi":"10.1038/s41391-025-01070-8","tag_type":"warning","value":"High exclusion due to tissue insufficiency/older FFPE may introduce selection bias.","value_numeric":null}],"summaries":{"what_studied":"Retrospective validation of the Prostatype P-score (3-gene RT‑qPCR with PSA, stage, and grade) to predict prostate cancer–specific mortality in a multiethnic U.S. VA cohort of newly diagnosed, clinically localized prostate cancer; 160 biopsy samples met assay criteria with a median follow-up of 7.5 years, and performance was compared with PSA, grade, and NCCN risk group.","key_result":"Among 160 patients (14 prostate cancer deaths over 7.5 years), each 1‑point higher P-score was associated with higher PC‑specific mortality (HR 1.48, 95% CI 1.20–1.84; p<0.001) with strong discrimination (c‑index 0.87; 10‑year AUC 0.80). Adding clinical variables minimally improved accuracy; decision curve analysis showed net benefit for risk thresholds from 5% to ~50%, and in intermediate‑risk patients the P‑score remained predictive (Fine‑Gray HR 1.43, 95% CI 1.09–1.86; p=0.009).","limitations":"Final N was modest (n=160) with few prostate cancer deaths (n=14), limiting multivariable adjustment and power. Large attrition from tissue insufficiency and older FFPE blocks may introduce selection bias, and this was a single-center VA cohort with heterogeneous treatments not stratified.","practice_takeaway":"In this VA cohort, the P-score predicted prostate cancer–specific mortality more accurately than PSA or grade, with little incremental value from adding clinical variables. Where available, it can refine risk stratification—including in intermediate‑risk patients—across decision thresholds commonly used in practice."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Genomic Classifier"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Genomic Classifier"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Genomic Classifier"}}}]]

Papers